Introduction: Epithelial ovarian cancer (EOC) is primarily confined to the peritoneal cavity. When primary complete surgery is not possible, neoadjuvant chemotherapy (NACT) is provided; however, the peritoneum-plasma barrier hinders the drug effect. The intraperitoneal administration of chemotherapy could eliminate residual microscopic peritoneal tumor cells and increase this effect by hyperthermia. Intraperitoneal hyperthermic chemotherapy (HIPEC) after interval cytoreductive surgery could improve outcomes in terms of disease-free survival (DFS) and overall survival (OS). Materials and Methods: A multicenter, retrospective observational study of advanced EOC patients who underwent interval cytoreductive surgery alone (CRSnoH) or interval cytoreductive surgery plus HIPEC (CRSH) was carried out in Spain between 07/2012 and 12/2021. A total of 515 patients were selected. Progression-free survival (PFS) and OS analyses were performed. The series of patients who underwent CRSH or CRSnoH was balanced regarding the risk factors using a statistical analysis technique called propensity score matching. Results: A total of 170 patients were included in each subgroup. The complete surgery rate was similar in both groups (79.4% vs. 84.7%). The median PFS times were 16 and 13 months in the CRSH and CRSnoH groups, respectively (Hazard ratio (HR) 0.74; 95% CI, 0.58–0.94;p= 0.031). The median OS times were 56 and 50 months in the CRSH and CRSnoH groups, respectively (HR, 0.88; 95% CI, 0.64–1.20;p= 0.44). There was no increase in complications in the CRSH group. Conclusion: The addition of HIPEC after interval cytoreductive surgery is safe and increases DFS in advanced EOC patients.
引言：上皮性卵巢癌（EOC）主要局限于腹膜腔。当无法进行初次完全手术时，会采用新辅助化疗（NACT）；然而，腹膜-血浆屏障会阻碍药物效果。腹腔内化疗可消除残留的微小腹膜肿瘤细胞，并通过热疗增强此效果。间歇性肿瘤细胞减灭术后进行腹腔热灌注化疗（HIPEC）可改善无病生存期（DFS）和总生存期（OS）的预后。材料与方法：2012年7月至2021年12月期间，在西班牙对接受单纯间歇性肿瘤细胞减灭术（CRSnoH）或间歇性肿瘤细胞减灭术联合HIPEC（CRSH）的晚期EOC患者进行了一项多中心回顾性观察研究。共纳入515名患者。进行了无进展生存期（PFS）和OS分析。通过倾向评分匹配的统计分析技术，使接受CRSH或CRSnoH的患者系列在风险因素方面达到平衡。结果：每个亚组各纳入170名患者。两组的完全手术率相似（79.4% vs. 84.7%）。CRSH组和CRSnoH组的中位PFS时间分别为16个月和13个月（风险比（HR）0.74；95% CI，0.58–0.94；p=0.031）。CRSH组和CRSnoH组的中位OS时间分别为56个月和50个月（HR，0.88；95% CI，0.64–1.20；p=0.44）。CRSH组的并发症并未增加。结论：在间歇性肿瘤细胞减灭术后增加HIPEC是安全的，并能提高晚期EOC患者的DFS。
肿瘤(癌症)患者之家